Express . . . The FDA approves new treatment options for blood cancer by changing intravenous lystoy.

▎ editor of the content team of pharmaceutics, the US Food and Drug Administration (FDA) announced today that it has approved the launch of inqovi (decitabine and cedazuridine) tablets developed by Astex pharmaceuticals of Otsuka pharmaceutical company for the treatment of adult patients with myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML).this represents an important improvement in the treatment options of patients with MDs who previously needed intravenous treatment in healthcare institutions.in the context of the covid-19 pandemic, this brings them more risk of infection.inqovi is an oral tablet composed of the chemotherapeutic drugs decitabine and cedazuridine.decitabine is an approved DNA demethylation agent, while cedazuridine can inhibit cytidine deaminase in intestine and liver and avoid degradation of decitabine, thus enabling inqovi to be administered orally.clinical trial results showed that the concentration of decitabine in patients was similar to that of oral inqovi.in addition, about half of patients who previously relied on blood transfusion no longer need blood transfusion within 8 weeks of treatment.the safety characteristics of inqovi were similar to those of intravenous sitabine.this innovative treatment option has been granted orphan drug qualification by FDA, and its marketing application has also been given priority review qualification."FDA remains committed to providing patients with more treatment options during the covid-19 pandemic.today's approval provides an oral treatment option that can be taken at home, which can reduce the need for patients to visit medical institutions frequently, "said Richard, director of the FDA center of excellence in oncology and acting director of the office of oncology, FDA Center for drug evaluation and research "At this critical moment, we continue to focus on options for cancer patients, including options that can be taken at home," Dr. pazdur said."reference materials: [1] FDA approved new therapy for myelodysplastic compounds (MDS) that can be taken at home. Retrieved July 7, 2020, from.if you need guidance on treatment plan, please go to a regular hospital.